MedWatch

Analyst: Novo Nordisk's estimated sales growth decrease not as big as expected

A general price squeeze and lower sales in China will be evident in Novo Nordisk's sales growth next year, but the predicted impact is less significant than anticipated, says a Sydbank analyst.

Photo: Novo Nordisk / PR

On Friday, Novo Nordisk reports that global sales growth will be negatively affected by a 3 percent sales growth decrease in 2022 because of a new Chinese insulin tender model, resulting in lower prices and volumes of insulin sold in China.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs